Table 1 Baseline characteristics of patients with NRG1 fusion and non-fusion
From: Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors
Characteristic | Fusion (n = 49) | Non-fusion (n = 25,154) |
|---|---|---|
Sex, n (%) | Â | Â |
Male | 18 (36.7%) | 14522 (57.7%) |
Female | 31 (63.3%) | 10632 (42.3%) |
Age, n (%) | Â | Â |
>60 | 33 (67.3%) | 12865 (51.1%) |
≤60 | 16 (32.7%) | 12289 (48.9%) |
Stage, n (%) | Â | Â |
I | 0 | 480 (1.9%) |
II | 2 (4.1%) | 843 (3.4%) |
III | 0 | 1646 (6.5%) |
IV | 8 (16.3%) | 5275 (21.0%) |
Unknown | 39 (79.6%) | 16910 (67.2%) |
Diagnosis, n (%) | Â | Â |
Lung cancer | 36 (73.5%) | 12422 (49.4%) |
Colorectal cancer | 3 (6.1%) | 2799 (11.1%) |
Breast cancer | 3 (6.1%) | 632 (2.5%) |
Gastric cancer | 2 (4.1%) | 1510 (6.0%) |
Liver cancer | 1 (2.0%) | 2137 (8.5%) |
Esophageal cancer | 1 (2.0%) | 393 (1.6%) |
Pancreatic cancer | 1 (2.0%) | 932 (3.7%) |
Prostate cancer | 1 (2.0%) | 154 (0.6%) |
Medulloblastoma | 1 (2.0%) | 12 (0.1%) |
Sarcomas | 0 | 662 (2.6%) |
Glioma | 0 | 516 (2.1%) |
Head and neck cancer | 0 | 432 (1.7%) |
Cervical cancer | 0 | 398 (1.6%) |
Cholangiocarcinoma | 0 | 272 (1.1%) |
Other | 0 | 1883 (7.5%) |
